Gut Microbiota Research & Practice is a section dedicated to promoting knowledge-sharing and debate among researchers, scientists and healthcare professionals. You will find a selection of discussions about articles from scientific literature as well as other content including interviews with experts, event reports, and special publications.
by Giovana Martucelli
A new study sheds light on how gut microbiota-derived metabolites can influence host immune and metabolic pathways. Focusing on trimethylamine (TMA) and IRAK4 signaling, the findings help clarify the mechanisms linking microbial metabolism with metabolic inflammation and glycemic regulation.
by Giovana Martucelli
Blastocystis has long been viewed mainly as a marker of parasitic infection. Emerging research reviewed here suggests that its presence is not necessarily linked to disease, but may instead reflect greater microbial diversity and metabolic health in certain contexts.
Alterations in the composition and function of the gut microbiota are recognized as key contributors to the pathophysiology of IBS. In this interview with Prof. Carmelo Scarpignato, we discuss the knowns and unknowns of gut microbiota in IBS, the four levels of gut microbiota manipulation, and examples of microbiota-targeted approaches available for the clinician.
The fifth edition of IBS Days delved into the latest developments in IBS research and clinical management. This article aims to explore causes that can be misdiagnosed as IBS and non-pharmacological strategies targeting gut barrier and gut microbiome dysfunction.
by Andreu Prados
While diet is a major determinant of the human gut microbiome, little is known about diet-microbiome associations at species-level resolution. New findings from the Human Phenotype Project found species-level, food-specific associations validated at population scale that might guide personalized nutrition.
by Andreu Prados
Digestive symptoms with an impact on quality of life (QoL) affect one in four adults in the general population worldwide who do not qualify for a diagnosis of a Disorder of Gut-Brain Interaction (DGBI). Recent research suggests this ‘sub-diagnostic’ group demands additional investigation and might benefit from targeted interventions, including dietary interventions.
by Konstantina Zafeiropoulou
The European regulatory landscape for microbiome-based therapies is rapidly evolving. New frameworks like the SoHO Regulation aim to harmonize safety, quality, and access across countries. This article explores the current challenges, opportunities, and expert perspectives shaping the field.
by GMFH Editing Team
The role of diet and the gut microbiome in inflammatory bowel disease (IBD) continues to evolve, from shaping disease risk to supporting treatment strategies. In this interview with Richard Hansen and Chen Sarbagili, we discuss key misconceptions, emerging evidence, and what the future may hold for microbiome-based approaches in IBD.
by Andreu Prados
With nearly 240 participants from 27 countries, the 14th edition of GMFH World Summit covered basic, translational and clinical science supporting the integration of microbiome-targeted interventions into preventive and therapeutic strategies for gastrointestinal disorders, cardiometabolic diseases, and cancer.
by Heather Galipeau, Mark Wulczynski
A new study reveals that the benefits of dietary fiber in celiac disease depend not only on intake, but also on the presence of specific gut microbes capable of metabolizing it. These findings highlight the need for more personalized dietary strategies beyond the gluten-free diet.
